LIGHT-VTP normalizes tumor vasculature and triggers lymphoid aggregate.36 The AAV-LIGHT therapy modulates the vascular phenotype, eliciting the formation of HEVs and TLSs, which prolong the survival of mice with gliomas resistant to anti-PD-1 treatment.320 Furthermore, HEV neogenesis also relies on TNFR signaling. The gene discussed is TNFSF14; the disease is neoplasm.